TVTX · NASDAQ
Travere Therapeutics, Inc.
$50.50 -0.15 (-0.29%)
Company overview
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivery of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $4.8B
- Employees
- 385
- Headquarters
- San Diego, CA
- Website
- travere.com
- CEO
- Eric Dube
- Listed
- November 8, 2012
- P/E
- -103.06
- Dividend yield
- 0.00%
Company financials
- Revenue
- $536M
- Gross profit
- $504M
- Operating income
- -$57.1M
- EBITDA
- $36M
- Net income
- -$21.4M
- EPS
- -$0.49
- Total assets
- $555M
- Total debt
- $328M
- Gross margin
- 93.95%
- Net margin
- -4.00%
- Earnings yield
- -0.97%
Showing FY 2025
TVTX
1D
NASDAQ
O52.00H52.22L49.78C50.05-2.38 (-4.54%)Vol433.68K